Donovan Polack, MD
Nephrology · Florissant, MONPI 1659324465
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.3% of the total across 180 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 12.1% — the pattern of someone who eats at a lot of different presentations.
Across 180 payments — averaging $27.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$588
- Fresenius USA Marketing, Inc.$518
- Amgen$481
- AstraZeneca$468
- Vifor Pharma, Inc.$368
- Mallinckrodt Enterprises LLC$281
- plus $2K from 20 others
Across 425 payments — averaging $1829.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$344K
- Akebia Therapeutics Inc$190K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$95K
- Bayer$79K
- Vertex$63K
- Ardelyx, Inc.$6K
What the payments were for
- Food & beverage$4,63795%
- Education$2275%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 25 | $588 |
| Fresenius USA Marketing, Inc. | 16 | $518 |
| Amgen | 21 | $481 |
| AstraZeneca(2 entities) | 24 | $468 |
| Vifor Pharma, Inc. | 21 | $368 |
| Mallinckrodt Enterprises LLC | 5 | $281 |
| Calliditas Therapeutics US Inc. | 7 | $268 |
| Travere Therapeutics, Inc. | 9 | $265 |
| Nxstage Medical, Inc. | 2 | $247 |
| OPKO Pharmaceuticals, LLC | 8 | $225 |
| Ardelyx, Inc. | 4 | $184 |
| Boehringer Ingelheim | 7 | $156 |
| Astrazeneca UK Limited | 1 | $135 |
| Bayer | 5 | $92 |
| Novartis | 3 | $86 |
| Lilly USA, LLC | 3 | $79 |
| Mallinckrodt Hospital Products Inc. | 3 | $70 |
| Akebia Therapeutics Inc | 3 | $67 |
| GSK | 3 | $66 |
| Vertex | 1 | $56 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $40 |
| Cormedix Inc. | 1 | $36 |
| Merck | 2 | $29 |
| Cumberland Pharmaceuticals, Inc. | 2 | $25 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NXSTAGE SYSTEM ONE$333
- Filspari$125
- VOYXACT$123
- TARPEYO$123
- ACTHAR$122
- Velphoro$121
- XPHOZAH 30 MG$117
- LIBERTY SELECT CYCLER$112
- Rayaldee$111
How this compares
$4,864 in reported general payments places this provider in the 80th percentile of 253 nephrology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 296 | $245,535 |
| VelphoroSucroferric Oxyhydroxide | 54 | $109,364 |
| RayaldeeCalcifediol | 33 | $46,687 |
| JardianceEmpagliflozin | 41 | $39,710 |
| Lanthanum Carbonate | 17 | $33,817 |
| OzempicSemaglutide | 19 | $24,561 |
| Sevelamer Carbonate | 90 | $22,031 |
| LokelmaSodium Zirconium Cyclosilicate | 15 | $16,701 |
| VeltassaPatiromer Calcium Sorbitex | 15 | $15,016 |
| DapagliflozinDapagliflozin Propanediol | 18 | $13,072 |
| InvokanaCanagliflozin | 15 | $8,654 |
| Nifedipine ErNifedipine | 49 | $1,946 |
| Chlorthalidone | 67 | $1,295 |
| Losartan Potassium | 143 | $1,029 |
| Carvedilol | 143 | $894 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $468 | $262,236311 claims |
| Fresenius USA Marketing, Inc.Velphoro | $518 | $109,36454 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $225 | $46,68733 claims |
| Boehringer IngelheimJardiance | $156 | $39,71041 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 253 nephrology providers in Missouri.
Other nephrology in Florissant
- Alejandro AlvarezFlorissant$176K
- Derek LarsonCreve Coeur$605K
- Marcos RothsteinSaint Louis$350K
- Anuja JavaSaint Louis$240K
- Kevin MartinSt Louis$189K
- Gary SingerSaint Peters$170K
- Daniel CoyneSaint Louis$163K
- Tarek AlhamadSaint Louis$155K
- Tingting LiSaint Louis$130K
- Bahar BastaniSt Louis$87K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.